ChromaDex Co. (NASDAQ:CDXC) Expected to Announce Quarterly Sales of $19.97 Million

Analysts forecast that ChromaDex Co. (NASDAQ:CDXCGet Rating) will announce sales of $19.97 million for the current quarter, according to Zacks. Four analysts have made estimates for ChromaDex’s earnings, with estimates ranging from $18.71 million to $21.10 million. ChromaDex posted sales of $17.70 million during the same quarter last year, which would indicate a positive year over year growth rate of 12.8%. The company is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that ChromaDex will report full-year sales of $0.00 for the current fiscal year. For the next year, analysts forecast that the business will post sales of $101.54 million, with estimates ranging from $91.58 million to $113.84 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow ChromaDex.

ChromaDex (NASDAQ:CDXCGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ChromaDex had a negative net margin of 39.25% and a negative return on equity of 75.43%. During the same quarter in the prior year, the company posted ($0.12) EPS.

Several equities analysts have recently issued reports on CDXC shares. Roth Capital started coverage on shares of ChromaDex in a research note on Tuesday, March 8th. They set a “buy” rating and a $7.00 price target for the company. B. Riley decreased their price objective on shares of ChromaDex from $8.00 to $6.00 in a research report on Friday. StockNews.com began coverage on shares of ChromaDex in a research report on Thursday, March 31st. They set a “hold” rating for the company. HC Wainwright decreased their price objective on shares of ChromaDex from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, April 18th. Finally, Zacks Investment Research cut shares of ChromaDex from a “hold” rating to a “sell” rating in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.06.

CDXC stock opened at $1.69 on Friday. The company has a fifty day moving average price of $2.21 and a 200-day moving average price of $3.34. ChromaDex has a 52-week low of $1.51 and a 52-week high of $10.78.

In related news, CEO Robert N. Fried purchased 25,000 shares of ChromaDex stock in a transaction on Wednesday, March 16th. The stock was acquired at an average cost of $2.16 per share, for a total transaction of $54,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.84% of the company’s stock.

Large investors have recently bought and sold shares of the business. Citigroup Inc. grew its holdings in ChromaDex by 66.8% in the third quarter. Citigroup Inc. now owns 5,339 shares of the company’s stock worth $33,000 after purchasing an additional 2,139 shares during the period. Royal Bank of Canada increased its position in shares of ChromaDex by 70.8% during the third quarter. Royal Bank of Canada now owns 5,482 shares of the company’s stock worth $35,000 after acquiring an additional 2,273 shares in the last quarter. Advisor Group Holdings Inc. increased its position in shares of ChromaDex by 4,922.7% during the third quarter. Advisor Group Holdings Inc. now owns 7,735 shares of the company’s stock worth $49,000 after acquiring an additional 7,581 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of ChromaDex by 373.9% during the third quarter. BNP Paribas Arbitrage SA now owns 8,771 shares of the company’s stock worth $55,000 after acquiring an additional 6,920 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of ChromaDex during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 29.64% of the company’s stock.

ChromaDex Company Profile (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Further Reading

Get a free copy of the Zacks research report on ChromaDex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.